Multinational phase 1b study of cabozantinib plus atezolizumab for advanced renal cell carcinoma

Cabozantinib and atezolizumab have demonstrated activity against solid tumors as single agents and in combination regimens. The multinational phase 1b study COSMIC-021 evaluates cabozantinib plus atezolizumab for various advanced solid tumors. In the cohorts with advanced clear cell renal cell carcinoma and advanced non-clear cell renal cell carcinoma the combination had acceptable tolerability and encouraging clinical activity.